Apogee Therapeutics (APGE) Income from Continuing Operations (2022 - 2026)
Apogee Therapeutics' (APGE) quarterly Income from Continuing Operations came in at 74111000.0 in Q1 2026, down 33.92% year-on-year from 112156551.78 in Q1 2025, and down 379.99% on a QoQ basis from 15440000.0 in Q4 2025.
Apogee Therapeutics (APGE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 5 years of Income from Continuing Operations data on file, last reported at 74111000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 33.92% year-over-year to 74111000.0 in Q1 2026; TTM through Mar 2026 was 220668000.0, a 7.73% decrease from a year earlier, with the FY2025 full-year figure at 201896000.0, down 11.18% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 74111000.0, down from 15440000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for APGE reached as high as 1816000.0 in Q2 2022 and fell as low as 74111000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 37886125.0 across 5 years, with a median of 32955000.0 in 2024.
- Across the five-year window, Income from Continuing Operations slumped 939.92% in 2023 and surged 76.84% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 20782000.0 in 2022, then sank by 197.92% to 61913000.0 in 2023, then dropped by 7.66% to 66658000.0 in 2024, then jumped by 76.84% to 15440000.0 in 2025, then plunged by 379.99% to 74111000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 74111000.0 in Q1 2026, 15440000.0 in Q4 2025, and 65021000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Apogee Therapeutics | 9.36 Bn | 8.30 Bn | - | -74.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.11 Mn |
| Dec 31, 2025 | -15.44 Mn |
| Sep 30, 2025 | -65.02 Mn |
| Jun 30, 2025 | -66.10 Mn |
| Mar 31, 2025 | -55.34 Mn |
| Dec 31, 2024 | -66.66 Mn |
| Sep 30, 2024 | -49.02 Mn |
| Jun 30, 2024 | -33.82 Mn |
| Mar 31, 2024 | -32.09 Mn |
| Dec 31, 2023 | -61.91 Mn |
| Sep 30, 2023 | -22.16 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.53 Mn |
| Dec 31, 2022 | -20.78 Mn |
| Sep 30, 2022 | -10.51 Mn |
| Jun 30, 2022 | -1.82 Mn |